Cargando…

Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing

BACKGROUND: Trimethylaminuria (TMAU) is a metabolic disorder characterized by the excessive excretion of the malodorous compound trimethylamine (TMA). The diagnosis of TMAU is challenging because this disorder is situated at the boundary between biochemistry and psychiatry. Here, we used nuclear mag...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouchemal, Nadia, Ouss, Lisa, Brassier, Anaïs, Barbier, Valérie, Gobin, Stéphanie, Hubert, Laurence, de Lonlay, Pascale, Le Moyec, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751875/
https://www.ncbi.nlm.nih.gov/pubmed/31533761
http://dx.doi.org/10.1186/s13023-019-1174-6
_version_ 1783452703680102400
author Bouchemal, Nadia
Ouss, Lisa
Brassier, Anaïs
Barbier, Valérie
Gobin, Stéphanie
Hubert, Laurence
de Lonlay, Pascale
Le Moyec, Laurence
author_facet Bouchemal, Nadia
Ouss, Lisa
Brassier, Anaïs
Barbier, Valérie
Gobin, Stéphanie
Hubert, Laurence
de Lonlay, Pascale
Le Moyec, Laurence
author_sort Bouchemal, Nadia
collection PubMed
description BACKGROUND: Trimethylaminuria (TMAU) is a metabolic disorder characterized by the excessive excretion of the malodorous compound trimethylamine (TMA). The diagnosis of TMAU is challenging because this disorder is situated at the boundary between biochemistry and psychiatry. Here, we used nuclear magnetic resonance spectroscopy to assess TMAU in 13 patients. We also sequenced the FMO3 gene in 11 of these patients. Treatment with vitamin B2 was prescribed. RESULTS: Two patients (aged 3 and 9 years at the initial consultation) had a particularly unpleasant body odor, as assessed by their parents and the attending physicians. The presence of high urine TMA levels confirmed the presence of a metabolic disorder. The two (unrelated) children carried compound heterozygous variants in the FMO3 gene. In both cases, vitamin B2 administration decreased TMA excretion and reduced body odor. The 11 adults complained of an unpleasant body odor, but the physicians did not confirm this. In all adult patients, the urine TMA level was within the normal range reported for control (non-affected) subjects, although two of the patients displayed an abnormally high proportion of oxidized TMA. Seven of the 9 tested adult patients had a hypomorphic variant of the FMO3 gene; the variant was found in the homozygous state, in the heterozygous state or combined with another hypomorphic variant. All 11 adults presented a particular psychological or psychiatric phenotype, with a subjective perception of unpleasant odor. CONCLUSIONS: The results present the clinical and biochemical data of patients complaining of unpleasant body odor. Contrary to adult patients, the two children exhibited all criteria of recessively inherited trimethylaminuria, suspected by parents in infancy. B2 vitamin treatment dramatically improved the unpleasant body odor and the ratio of TMA/Cr vs TMAO/Cr in the urine in the children. Other patients presented a particular psychological or psychiatric phenotype.
format Online
Article
Text
id pubmed-6751875
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67518752019-09-23 Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing Bouchemal, Nadia Ouss, Lisa Brassier, Anaïs Barbier, Valérie Gobin, Stéphanie Hubert, Laurence de Lonlay, Pascale Le Moyec, Laurence Orphanet J Rare Dis Research BACKGROUND: Trimethylaminuria (TMAU) is a metabolic disorder characterized by the excessive excretion of the malodorous compound trimethylamine (TMA). The diagnosis of TMAU is challenging because this disorder is situated at the boundary between biochemistry and psychiatry. Here, we used nuclear magnetic resonance spectroscopy to assess TMAU in 13 patients. We also sequenced the FMO3 gene in 11 of these patients. Treatment with vitamin B2 was prescribed. RESULTS: Two patients (aged 3 and 9 years at the initial consultation) had a particularly unpleasant body odor, as assessed by their parents and the attending physicians. The presence of high urine TMA levels confirmed the presence of a metabolic disorder. The two (unrelated) children carried compound heterozygous variants in the FMO3 gene. In both cases, vitamin B2 administration decreased TMA excretion and reduced body odor. The 11 adults complained of an unpleasant body odor, but the physicians did not confirm this. In all adult patients, the urine TMA level was within the normal range reported for control (non-affected) subjects, although two of the patients displayed an abnormally high proportion of oxidized TMA. Seven of the 9 tested adult patients had a hypomorphic variant of the FMO3 gene; the variant was found in the homozygous state, in the heterozygous state or combined with another hypomorphic variant. All 11 adults presented a particular psychological or psychiatric phenotype, with a subjective perception of unpleasant odor. CONCLUSIONS: The results present the clinical and biochemical data of patients complaining of unpleasant body odor. Contrary to adult patients, the two children exhibited all criteria of recessively inherited trimethylaminuria, suspected by parents in infancy. B2 vitamin treatment dramatically improved the unpleasant body odor and the ratio of TMA/Cr vs TMAO/Cr in the urine in the children. Other patients presented a particular psychological or psychiatric phenotype. BioMed Central 2019-09-18 /pmc/articles/PMC6751875/ /pubmed/31533761 http://dx.doi.org/10.1186/s13023-019-1174-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Bouchemal, Nadia
Ouss, Lisa
Brassier, Anaïs
Barbier, Valérie
Gobin, Stéphanie
Hubert, Laurence
de Lonlay, Pascale
Le Moyec, Laurence
Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing
title Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing
title_full Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing
title_fullStr Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing
title_full_unstemmed Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing
title_short Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing
title_sort diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)h nmr spectroscopy and genetic testing
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751875/
https://www.ncbi.nlm.nih.gov/pubmed/31533761
http://dx.doi.org/10.1186/s13023-019-1174-6
work_keys_str_mv AT bouchemalnadia diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting
AT ousslisa diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting
AT brassieranais diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting
AT barbiervalerie diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting
AT gobinstephanie diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting
AT hubertlaurence diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting
AT delonlaypascale diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting
AT lemoyeclaurence diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting